Interleukin-4 stimulates papillary thyroid cancer cell survival: Implications in patients with thyroid cancer and concomitant Graves' disease

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 6, 2004, Pages 2880-2889

  Vella, Veronica ^a   Mineo, Rossana ^a   Frasca, Francesco ^a   Mazzon, Emanuela ^b   Pandini, Giuseppe ^a   Vigneri, Riccardo ^a   Belfiore, Antonino ^c,d  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d Policlinico Mater Domini   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ALPHA; PROTEIN BAX; RECEPTOR SUBTYPE; STAUROSPORINE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURFACE; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; GRAVES DISEASE; HISTOPATHOLOGY; HORMONE ACTION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; T LYMPHOCYTE ACTIVATION; TH2 CELL; THYROID CARCINOMA; TISSUE SECTION;

APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, PAPILLARY; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GRAVES DISEASE; HUMANS; INTERLEUKIN-4; NEOPLASM INVASIVENESS; RECEPTORS, INTERLEUKIN-4; TH2 CELLS; THYROID NEOPLASMS;

MINK CELL FOCUS-FORMING VIRUS;

EID: 2942644653     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031639     Document Type: Conference Paper

References (33)

1. Collins J, Gough S 2002 Autoimmunity in thyroid disease. Eur J Nucl Med Mol Imaging 29(Suppl 2):S417-S424
2. Belfiore A, Russo D, Vigneri R, Filetti S 2001 Graves' disease, thyroid nodules and thyroid cancer. Clin Endocrinol (Oxf) 55:711-718
3. Belfiore A, Garofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A, Ippolito O, Vigneri R 1990 Increased aggressiveness of thyroid cancer in patients with Graves' disease. J Clin Endocrinol Metab 70:830-835
4. Pellegriti G, Belfiore A, Giuffrida D, Lupo L, Vigneri R 1998 Outcome of differentiated thyroid cancer in Graves' patients. J Clin Endocrinol Metab 83:2805-2809
5. Filetti S, Belfiore A, Amir SM, Daniels GH, Ippolito O, Vigneri R, Ingbar SH 1988 The role of thyroid-stimulating antibodies of Graves' disease in differentiated thyroid cancer. N Engl J Med 318:753-759
6. Roura-Mir C, Catalfamo M, Sospedra M, Alcalde L, Pujol-Borrell R, Jaraquemada D 1997 Single-cell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto's and Graves' disease. Eur J Immunol 27:3290-3302
7. Heuer M, Aust G, Ode-Hakim S, Scherbaum WA 1996 Different cytokine mRNA profiles in Graves' disease, Hashimoto's thyroiditis, and nonautoimmune thyroid disorders determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Thyroid 6:97-106
8. Al-Humaidi MA 2000 Serum cytokines levels in Graves' disease. Saudi Med J 21:639-644
9. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE 1999 The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17:701-738
10. Monroe JG, Haldar S, Prystowsky MB, Lammie P 1988 Lymphokine regulation of inflammatory processes: interleukin-4 stimulates fibroblast proliferation. Clin Immunol Immunopathol 49:292-298
11. Toi M, Bicknell R, Harris AL 1992 Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 52:275-279
12. Obiri NI, Hillman GG, Haas GP, Sud S, Puri RK 1993 Expression of high affinity interleukin-4 s on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 91:88-93
13. Gooch JL, Lee AV, Yee D 1998 Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res 58:4199-4205
14. Heo DS, Park JG, Hata K, Day R, Herberman RB, Whiteside TL 1990 Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res 50:3681-3690
15. Hollingsworth SJ, Darling D, Gaken J, Hirst W, Patel P, Kuiper M, Towner P, Humphreys S, Farzaneh F, Mufti GJ 1996 The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma. Br J Cancer 74:6-15
16. Myers JN, Yasumura S, Suminami Y, Hirabayashi H, Lin W, Johnson JT, Lotze MT, Whiteside TL 1996 Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res 2:127-135
17. Fisfalen ME, Palmer EM, Van Seventer GA, Soltani K, Sawai Y, Kaplan E, Hidaka Y, Ober C, DeGroot LJ 1997 Thyrotropin-receptor and thyroid peroxidase-specific T cell clones and their cytokine profile in autoimmune thyroid disease. J Clin Endocrinol Metab 82:3655-3663
18. Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di Gesu G, De Maria R 2003 Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 63:6784-6790
19. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, Belfiore A 2002 A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87:245-254
20. Stracke ML, Kohn EC, Aznavoorian SA, Wilson LL, Salomon D, Krutzsch HC, Liotta LA, Schiffmann E 1988 Insulin-like growth factors stimulate chemotaxis in human melanoma cells. Biochem Biophys Res Commun 153:1076-1083
21. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R, Belfiore A 2002 In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 21:8240-8250
22. Bartucci M, Morelli C, Mauro L, Ando S, Surmacz E 2001 Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 61:6747-6754
23. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X 1997 Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129-1132
24. Cory S 1995 Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 13:513-543
25. Akbar AN, Borthwick NJ, Wickremasinghe RG, Panayoitidis P, Pilling D, Bofill M, Krajewski S, Reed JC, Salmon M 1996 Interleukin-2 receptor common γ-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur J Immunol 26: 294-299
26. Ekert PG, Silke J, Vaux DL 1999 Caspase inhibitors. Cell Death Differ 6:1081-1086
27. Stassi G, Di Liberto D, Todaro M, Zeuner A, Ricci-Vitiani L, Stoppacciaro A, Ruco L, Farina F, Zummo G, De Maria R 2000 Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nat Immunol 1:483-488
28. Sherr CJ 1996 Cancer cell cycles. Science 274:1672-1677
29. Schwartz GK 2002 CDK inhibitors: cell cycle arrest versus apoptosis. Cell Cycle 1:122-123
30. Vidal A, Koff A 2000 Cell-cycle inhibitors: three families united by a common cause. Gene 247:1-15
31. Moller MB 2000 P27 in cell cycle control and cancer. Leuk Lymphoma 39:19-27
32. Vella V, Sciacca L, Pandini G, Mineo R, Squatrito S, Vigneri R, Belfiore A 2001 The IGF system in thyroid cancer: new concepts. Mol Pathol 54:121-124
33. Cantalamessa L, Baldini M, Orsatti A, Meroni L, Amodei V, Castagnone D 1999 Thyroid nodules in Graves' disease and the risk of thyroid carcinoma. Arch Intern Med 159:1705-1708